British pharmaceutical company GlaxoSmithKline on Sunday submitted an application to China's State Drug Administration to produce the combination anti-HIV pill Combivir locally in Tianjin, China. If approved, Glaxo will be the first international drugmaker to manufacture an anti-HIV drug in China. The Tianjin plant would be able to start producing Combivir by the end of 2004. The domestically produced medication would cost significantly less than imported versions of the two-drug combination pill, Glaxo officials said. Combivir contains the nucleoside reverse transcriptase inhibitors 3TC and AZT.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














